Registration Dossier

Administrative data

Description of key information

Based on the results of a dose range finding study with analogue 1,4 -H6XDI it was concluded that a repeated dose study with the undiluted substance is not possible. Taking into account that it was impossible to develop an analytical method it was concluded that it is technically not feasible to dose animals to a stable form of the test item and to conduct a repeated dose study. The considerations are also included in the read across document, attached in Section 13.

Key value for chemical safety assessment

Repeated dose toxicity: via oral route - systemic effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: inhalation - systemic effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: inhalation - local effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: dermal - systemic effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: dermal - local effects

Endpoint conclusion
Endpoint conclusion:
no study available

Additional information

Justification for classification or non-classification

In absence of data on repeated dose toxicity due to the fact that testing was found to be technically not feasible, 1,3-H6XDI is not classified for repeated dose toxicity according to the CLP Regulation (EC) No. 1272/2008.